PFEUSNASDAQ / NYSE · United States
PFIZER INC. (PFE)
28.89USD+0.21%close 2026-11-13
Daily candles · 12 months
PFE · 1DPerformance
1W
-1.7%1M
-1.9%3M
+7.5%6M
+14.1%YTD
+16.0%1Y
+15.3%52W low 23.62high 31.44
-8.1% from the 52-week high.
Trend
- vs 20-day average
- Below by 3.0%
- vs 50-day average
- Above by 0.3%
- vs 200-day average
- Above by 7.1%
- ATR (14d)
- 2.76%
- 10-day range
- 10.0%
- Volume vs 20-day avg
- 0.61×
Position size
- Risk per share
- 1.2 USD
- Shares
- 83
- Position value
- 2,397.87 USD
- % of account
- 24.0%
- Risk amount
- 99.6 USD
- 1R target
- 30.09
- 2R target
- 31.29
- 3R target
- 32.49
Fundamentals and earnings
- Market cap
- 164.67B
- P/E (trailing)
- 41.3
- P/E (forward)
- 9.8
- EPS (TTM / next yr)
- 0.70 / 2.95
- Dividend yield
- 7.46%
- Earnings date
- Feb 2, 2027 (est.)
Listing
- Ticker
- PFE US
- Yahoo / TradingView
- PFE · NYSE:PFE
- Keyword
- PFIZER
- Mapped to
- PFIZER INC. (PFE)PFE US
Headlines
- Pfizer (PFE) Stock Looks Overvalued On Its 29% One Year GainSimply Wall St. · 4d ago
- Can Moderna's First Cancer Therapy Win FDA Approval in 2027?Zacks · 5d ago
- Moderna Soars Another 9% as Piper Sandler Lifts Target to $305 on Raised OutlookTIKR · 5d ago
- Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028Motley Fool · 5d ago
- Medicus Pharma sharpens focus on Pfizer-licensed cancer drug CD228V, trims costs in Q3Proactive · 5d ago
- Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should KnowZacks · 5d ago
Prices and fundamentals from Yahoo Finance, delayed. Not financial advice.